| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuroblastoma | 22 | 2023 | 509 | 6.060 |
Why?
|
| Methotrexate | 4 | 2020 | 341 | 2.210 |
Why?
|
| Antimetabolites, Antineoplastic | 3 | 2020 | 178 | 1.820 |
Why?
|
| Cyclopentanes | 2 | 2024 | 20 | 1.690 |
Why?
|
| Antineoplastic Agents | 6 | 2022 | 1661 | 1.550 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 5 | 2020 | 804 | 1.390 |
Why?
|
| Pyrimidines | 2 | 2024 | 373 | 1.360 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2024 | 1227 | 1.240 |
Why?
|
| Transplantation Conditioning | 2 | 2020 | 323 | 1.160 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2020 | 255 | 1.120 |
Why?
|
| Hepatoblastoma | 3 | 2024 | 178 | 1.090 |
Why?
|
| Neoplasms | 5 | 2024 | 2757 | 1.040 |
Why?
|
| Child | 38 | 2024 | 24234 | 0.990 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 4 | 2022 | 1198 | 0.980 |
Why?
|
| Bone Neoplasms | 2 | 2019 | 427 | 0.960 |
Why?
|
| Induction Chemotherapy | 3 | 2022 | 42 | 0.920 |
Why?
|
| Pediatrics | 4 | 2022 | 1138 | 0.870 |
Why?
|
| Child, Preschool | 20 | 2024 | 13886 | 0.810 |
Why?
|
| Antibodies, Monoclonal | 2 | 2018 | 1007 | 0.790 |
Why?
|
| Adolescent | 21 | 2024 | 19102 | 0.760 |
Why?
|
| Liver Neoplasms | 4 | 2024 | 1308 | 0.740 |
Why?
|
| Legislation, Drug | 1 | 2020 | 9 | 0.730 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2020 | 31 | 0.730 |
Why?
|
| Algorithms | 2 | 2018 | 1592 | 0.720 |
Why?
|
| Neuroendocrine Tumors | 1 | 2021 | 52 | 0.710 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2020 | 38 | 0.710 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2020 | 29 | 0.700 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 80 | 0.690 |
Why?
|
| Sodium Bicarbonate | 1 | 2020 | 52 | 0.690 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2020 | 96 | 0.680 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2022 | 522 | 0.660 |
Why?
|
| Orchiectomy | 1 | 2019 | 44 | 0.650 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 1 | 2019 | 20 | 0.640 |
Why?
|
| Phenylurea Compounds | 1 | 2019 | 48 | 0.630 |
Why?
|
| Megakaryocyte Progenitor Cells | 1 | 2018 | 7 | 0.630 |
Why?
|
| Neutropenia | 1 | 2020 | 202 | 0.620 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2019 | 144 | 0.620 |
Why?
|
| Soft Tissue Neoplasms | 2 | 2021 | 130 | 0.620 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2019 | 88 | 0.620 |
Why?
|
| Periosteum | 1 | 2019 | 33 | 0.620 |
Why?
|
| Radiotherapy | 1 | 2019 | 135 | 0.620 |
Why?
|
| Enzyme Inhibitors | 1 | 2021 | 572 | 0.610 |
Why?
|
| Alemtuzumab | 1 | 2018 | 88 | 0.610 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2018 | 61 | 0.600 |
Why?
|
| Quinazolines | 1 | 2019 | 175 | 0.600 |
Why?
|
| Testicular Neoplasms | 1 | 2019 | 132 | 0.600 |
Why?
|
| Humans | 50 | 2024 | 123163 | 0.600 |
Why?
|
| Organophosphonates | 1 | 2018 | 19 | 0.600 |
Why?
|
| Twins, Monozygotic | 1 | 2018 | 117 | 0.600 |
Why?
|
| Cytosine | 1 | 2018 | 56 | 0.590 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2018 | 141 | 0.590 |
Why?
|
| Doxorubicin | 1 | 2019 | 299 | 0.580 |
Why?
|
| Neoplasms, Second Primary | 1 | 2019 | 151 | 0.580 |
Why?
|
| Bacterial Infections | 1 | 2020 | 305 | 0.580 |
Why?
|
| BK Virus | 1 | 2018 | 59 | 0.570 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2018 | 153 | 0.570 |
Why?
|
| Cystitis | 1 | 2018 | 50 | 0.570 |
Why?
|
| Tumor Virus Infections | 1 | 2018 | 134 | 0.560 |
Why?
|
| Polyomavirus Infections | 1 | 2018 | 90 | 0.560 |
Why?
|
| Infection Control | 1 | 2018 | 160 | 0.560 |
Why?
|
| Osteosarcoma | 1 | 2019 | 257 | 0.550 |
Why?
|
| Gene Rearrangement | 1 | 2018 | 326 | 0.540 |
Why?
|
| Apoptosis | 2 | 2021 | 1781 | 0.520 |
Why?
|
| Infant | 15 | 2024 | 12347 | 0.520 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 1239 | 0.500 |
Why?
|
| Thoracic Wall | 1 | 2015 | 36 | 0.500 |
Why?
|
| Survival Rate | 5 | 2024 | 1996 | 0.490 |
Why?
|
| Hematologic Neoplasms | 1 | 2018 | 286 | 0.490 |
Why?
|
| Lung Neoplasms | 2 | 2022 | 1582 | 0.470 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2024 | 1117 | 0.470 |
Why?
|
| Point-of-Care Systems | 1 | 2017 | 170 | 0.470 |
Why?
|
| Female | 24 | 2024 | 65489 | 0.450 |
Why?
|
| Off-Label Use | 1 | 2014 | 25 | 0.450 |
Why?
|
| Male | 21 | 2024 | 60082 | 0.440 |
Why?
|
| Retrospective Studies | 15 | 2024 | 16021 | 0.440 |
Why?
|
| NEDD8 Protein | 2 | 2024 | 11 | 0.430 |
Why?
|
| Disease Management | 1 | 2017 | 514 | 0.430 |
Why?
|
| Sarcoma | 1 | 2015 | 194 | 0.430 |
Why?
|
| Prognosis | 6 | 2024 | 4507 | 0.430 |
Why?
|
| Antiviral Agents | 1 | 2018 | 747 | 0.410 |
Why?
|
| Heart Defects, Congenital | 1 | 2024 | 1806 | 0.410 |
Why?
|
| Cell Proliferation | 1 | 2019 | 2306 | 0.390 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2022 | 66 | 0.380 |
Why?
|
| Follow-Up Studies | 6 | 2024 | 5046 | 0.380 |
Why?
|
| Young Adult | 7 | 2024 | 8862 | 0.360 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2019 | 1683 | 0.350 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 1262 | 0.340 |
Why?
|
| Drug Therapy | 1 | 2020 | 87 | 0.330 |
Why?
|
| Proton Therapy | 2 | 2022 | 123 | 0.330 |
Why?
|
| Emergencies | 1 | 2020 | 174 | 0.310 |
Why?
|
| Neoplasm, Residual | 3 | 2022 | 121 | 0.290 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2021 | 877 | 0.280 |
Why?
|
| Treatment Outcome | 4 | 2022 | 12129 | 0.280 |
Why?
|
| United States Food and Drug Administration | 2 | 2020 | 148 | 0.280 |
Why?
|
| Disease-Free Survival | 3 | 2022 | 861 | 0.260 |
Why?
|
| Cell Line, Tumor | 3 | 2022 | 3273 | 0.240 |
Why?
|
| Biopsy | 2 | 2018 | 1237 | 0.230 |
Why?
|
| Maximum Tolerated Dose | 1 | 2024 | 157 | 0.230 |
Why?
|
| Transplantation, Autologous | 2 | 2022 | 296 | 0.220 |
Why?
|
| Medical Oncology | 2 | 2022 | 214 | 0.220 |
Why?
|
| United States | 5 | 2024 | 10631 | 0.210 |
Why?
|
| N-Myc Proto-Oncogene Protein | 2 | 2022 | 56 | 0.210 |
Why?
|
| Tracheostomy | 1 | 2024 | 190 | 0.200 |
Why?
|
| Prospective Studies | 4 | 2022 | 6032 | 0.200 |
Why?
|
| Incidence | 3 | 2024 | 3047 | 0.190 |
Why?
|
| Thoracic Neoplasms | 1 | 2021 | 36 | 0.190 |
Why?
|
| Ganglioneuroblastoma | 1 | 2021 | 5 | 0.190 |
Why?
|
| Ganglioneuroma | 1 | 2021 | 17 | 0.190 |
Why?
|
| Polypharmacy | 1 | 2021 | 40 | 0.190 |
Why?
|
| MyoD Protein | 1 | 2021 | 21 | 0.190 |
Why?
|
| Radioisotopes | 1 | 2021 | 38 | 0.190 |
Why?
|
| Drug Interactions | 1 | 2022 | 254 | 0.190 |
Why?
|
| Receptors, Peptide | 1 | 2021 | 47 | 0.190 |
Why?
|
| Radionuclide Imaging | 1 | 2021 | 151 | 0.180 |
Why?
|
| Government Regulation | 1 | 2020 | 42 | 0.180 |
Why?
|
| Radiopharmaceuticals | 1 | 2021 | 156 | 0.180 |
Why?
|
| Hearing Loss | 1 | 2021 | 131 | 0.170 |
Why?
|
| Risk Factors | 3 | 2019 | 10008 | 0.170 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2024 | 714 | 0.170 |
Why?
|
| Animals | 6 | 2022 | 33752 | 0.170 |
Why?
|
| Fatty Acids | 1 | 2022 | 338 | 0.170 |
Why?
|
| Administration, Intravenous | 1 | 2020 | 143 | 0.170 |
Why?
|
| Medication Errors | 1 | 2021 | 184 | 0.170 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2020 | 102 | 0.170 |
Why?
|
| Drug Administration Schedule | 2 | 2021 | 729 | 0.160 |
Why?
|
| Vincristine | 1 | 2020 | 195 | 0.160 |
Why?
|
| Etoposide | 1 | 2019 | 117 | 0.160 |
Why?
|
| Positron-Emission Tomography | 1 | 2021 | 288 | 0.160 |
Why?
|
| Immunologic Factors | 1 | 2020 | 179 | 0.160 |
Why?
|
| Vocal Cord Paralysis | 1 | 2020 | 68 | 0.160 |
Why?
|
| Sodium | 1 | 2020 | 291 | 0.160 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 332 | 0.160 |
Why?
|
| Pulmonary Embolism | 1 | 2021 | 174 | 0.160 |
Why?
|
| Drug Synergism | 1 | 2019 | 239 | 0.160 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 186 | 0.160 |
Why?
|
| Cell Cycle | 1 | 2021 | 614 | 0.160 |
Why?
|
| Rhabdomyosarcoma | 1 | 2021 | 200 | 0.150 |
Why?
|
| Tumor Burden | 1 | 2019 | 229 | 0.150 |
Why?
|
| Drug Hypersensitivity | 1 | 2019 | 96 | 0.150 |
Why?
|
| Gangliosides | 1 | 2018 | 63 | 0.150 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 353 | 0.150 |
Why?
|
| Administration, Intravesical | 1 | 2018 | 31 | 0.150 |
Why?
|
| Desensitization, Immunologic | 1 | 2019 | 97 | 0.150 |
Why?
|
| Tissue Distribution | 1 | 2018 | 382 | 0.150 |
Why?
|
| Wilms Tumor | 1 | 2019 | 111 | 0.150 |
Why?
|
| Allografts | 1 | 2018 | 190 | 0.150 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 267 | 0.150 |
Why?
|
| Mice, Nude | 1 | 2019 | 694 | 0.150 |
Why?
|
| Blood Transfusion | 1 | 2019 | 301 | 0.140 |
Why?
|
| Lower Extremity | 1 | 2019 | 179 | 0.140 |
Why?
|
| Mucositis | 1 | 2017 | 18 | 0.140 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2021 | 715 | 0.140 |
Why?
|
| Bone Marrow | 1 | 2018 | 323 | 0.140 |
Why?
|
| Hodgkin Disease | 1 | 2019 | 293 | 0.140 |
Why?
|
| Adult | 6 | 2024 | 29057 | 0.140 |
Why?
|
| Risk | 1 | 2018 | 747 | 0.130 |
Why?
|
| Anticoagulants | 1 | 2021 | 581 | 0.130 |
Why?
|
| Thrombosis | 1 | 2021 | 520 | 0.130 |
Why?
|
| Fluid Therapy | 1 | 2017 | 121 | 0.130 |
Why?
|
| Area Under Curve | 1 | 2017 | 313 | 0.130 |
Why?
|
| Pilot Projects | 1 | 2020 | 1388 | 0.130 |
Why?
|
| Drug Monitoring | 1 | 2017 | 157 | 0.130 |
Why?
|
| Immunotherapy | 1 | 2020 | 653 | 0.130 |
Why?
|
| Chromosome Aberrations | 1 | 2018 | 614 | 0.130 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2024 | 935 | 0.120 |
Why?
|
| Infusions, Intravenous | 1 | 2017 | 536 | 0.120 |
Why?
|
| Immunoglobulin G | 1 | 2018 | 770 | 0.120 |
Why?
|
| Acute Disease | 1 | 2018 | 1094 | 0.120 |
Why?
|
| Infant, Newborn | 4 | 2024 | 8106 | 0.120 |
Why?
|
| Graft vs Host Disease | 1 | 2018 | 542 | 0.110 |
Why?
|
| Mice, Transgenic | 1 | 2019 | 2390 | 0.110 |
Why?
|
| Cytokines | 1 | 2018 | 1285 | 0.100 |
Why?
|
| Nervous System Diseases | 1 | 2017 | 372 | 0.100 |
Why?
|
| Age Factors | 1 | 2018 | 2802 | 0.100 |
Why?
|
| Signal Transduction | 2 | 2020 | 4493 | 0.090 |
Why?
|
| Acute Kidney Injury | 1 | 2017 | 609 | 0.080 |
Why?
|
| Transplantation, Homologous | 1 | 2011 | 659 | 0.080 |
Why?
|
| Mice | 2 | 2021 | 17492 | 0.070 |
Why?
|
| Biomedical Research | 1 | 2012 | 518 | 0.070 |
Why?
|
| Emergency Medical Services | 1 | 2020 | 435 | 0.060 |
Why?
|
| Drug Resistance | 1 | 2005 | 256 | 0.060 |
Why?
|
| Aspirin | 1 | 2005 | 224 | 0.050 |
Why?
|
| Genetic Markers | 1 | 2005 | 609 | 0.050 |
Why?
|
| Indazoles | 1 | 2022 | 23 | 0.050 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2005 | 257 | 0.050 |
Why?
|
| Protons | 1 | 2022 | 91 | 0.050 |
Why?
|
| Emergency Service, Hospital | 1 | 2020 | 1070 | 0.050 |
Why?
|
| Benzamides | 1 | 2022 | 106 | 0.050 |
Why?
|
| Dosage Forms | 1 | 2021 | 9 | 0.050 |
Why?
|
| Internship and Residency | 1 | 2012 | 1158 | 0.050 |
Why?
|
| Bays | 1 | 2021 | 6 | 0.050 |
Why?
|
| Medication Reconciliation | 1 | 2021 | 15 | 0.050 |
Why?
|
| Drug Storage | 1 | 2021 | 17 | 0.050 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2022 | 133 | 0.050 |
Why?
|
| Respiration, Artificial | 1 | 2024 | 451 | 0.050 |
Why?
|
| Pamphlets | 1 | 2021 | 23 | 0.050 |
Why?
|
| Maternal Age | 1 | 2022 | 136 | 0.050 |
Why?
|
| Thoracoscopy | 1 | 2021 | 41 | 0.050 |
Why?
|
| Communication Barriers | 1 | 2021 | 39 | 0.050 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2022 | 211 | 0.050 |
Why?
|
| Nonprescription Drugs | 1 | 2021 | 46 | 0.050 |
Why?
|
| Nephrectomy | 1 | 2022 | 172 | 0.050 |
Why?
|
| Coronary Disease | 1 | 2005 | 637 | 0.050 |
Why?
|
| Postoperative Complications | 2 | 2024 | 3013 | 0.050 |
Why?
|
| SEER Program | 1 | 2022 | 194 | 0.050 |
Why?
|
| Cranial Irradiation | 1 | 2021 | 69 | 0.050 |
Why?
|
| Operative Time | 1 | 2021 | 160 | 0.050 |
Why?
|
| Health Literacy | 1 | 2021 | 79 | 0.050 |
Why?
|
| Quinolines | 1 | 2021 | 96 | 0.040 |
Why?
|
| Vena Cava, Inferior | 1 | 2021 | 100 | 0.040 |
Why?
|
| Hoarseness | 1 | 2020 | 11 | 0.040 |
Why?
|
| Cisplatin | 1 | 2021 | 242 | 0.040 |
Why?
|
| Language | 1 | 2021 | 201 | 0.040 |
Why?
|
| Imidazoles | 1 | 2021 | 199 | 0.040 |
Why?
|
| Respiratory Sounds | 1 | 2020 | 69 | 0.040 |
Why?
|
| Relative Biological Effectiveness | 1 | 2019 | 6 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2022 | 550 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2022 | 1305 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2019 | 235 | 0.040 |
Why?
|
| Registries | 1 | 2024 | 1392 | 0.040 |
Why?
|
| Allergens | 1 | 2019 | 245 | 0.040 |
Why?
|
| Caregivers | 1 | 2021 | 572 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2005 | 2586 | 0.030 |
Why?
|
| Kidney | 1 | 2022 | 1337 | 0.030 |
Why?
|
| Parents | 1 | 2021 | 1030 | 0.030 |
Why?
|
| Texas | 1 | 2022 | 3555 | 0.030 |
Why?
|
| Genomics | 1 | 2021 | 1478 | 0.030 |
Why?
|
| Hawaii | 1 | 2012 | 6 | 0.030 |
Why?
|
| Publications | 1 | 2012 | 33 | 0.030 |
Why?
|
| Faculty | 1 | 2012 | 100 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2012 | 217 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2019 | 4705 | 0.020 |
Why?
|
| Pregnancy | 1 | 2022 | 7146 | 0.020 |
Why?
|
| Mutation | 1 | 2021 | 5773 | 0.020 |
Why?
|
| Aged | 1 | 2024 | 19080 | 0.020 |
Why?
|
| Mathematical Computing | 1 | 2005 | 9 | 0.020 |
Why?
|
| Receptors, Purinergic P2Y1 | 1 | 2005 | 12 | 0.020 |
Why?
|
| Receptors, Purinergic P2 | 1 | 2005 | 18 | 0.020 |
Why?
|
| Premedication | 1 | 2005 | 43 | 0.020 |
Why?
|
| Platelet Aggregation | 1 | 2005 | 120 | 0.010 |
Why?
|
| Middle Aged | 1 | 2024 | 25992 | 0.010 |
Why?
|
| Linkage Disequilibrium | 1 | 2005 | 310 | 0.010 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2005 | 172 | 0.010 |
Why?
|
| Homozygote | 1 | 2005 | 533 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2005 | 793 | 0.010 |
Why?
|
| Blood Platelets | 1 | 2005 | 333 | 0.010 |
Why?
|
| Exons | 1 | 2005 | 795 | 0.010 |
Why?
|
| Alleles | 1 | 2005 | 1603 | 0.010 |
Why?
|
| Genotype | 1 | 2005 | 2541 | 0.010 |
Why?
|